What Is SR9009?
SR9009, also known as Stenabolic, is a synthetic small-molecule agonist developed in work associated with Professor Thomas Burris at the Scripps Research Institute. It was designed to activate REV-ERB nuclear receptors, especially REV-ERBα and REV-ERBβ, sometimes written as Rev-ErbA and Rev-ErbB. These receptors are components of the molecular machinery that links the circadian clock with metabolism. Early laboratory studies reported that pharmacological activation of REV-ERB altered the expression of clock-related genes, increased energy expenditure, promoted fatty-acid oxidation, and changed metabolic physiology in mice. Those findings generated interest in obesity, metabolic syndrome, endurance, mitochondrial biology, and circadian-rhythm research.
SR9009 is not a SARM. SARMs act primarily at the androgen receptor, whereas SR9009 is intended to modulate transcription through REV-ERB receptors. The two categories are frequently grouped together by online vendors and performance-drug communities, but that classification is pharmacologically inaccurate. In mouse experiments, SR9009 was associated with changes in mitochondrial number and function and with increased fat oxidation, but these effects should not be interpreted as proven human effects. A major unresolved issue is oral bioavailability: much of the foundational animal work used subcutaneous administration, while many products marketed to people are oral preparations with uncertain absorption and identity. Public sources often describe an approximately four-hour half-life, although reliable human pharmacokinetic data are lacking. This has led to proposed multiple-daily dosing schedules, but no clinically validated schedule exists. SR9009 remains a research-only compound, and it has not been approved as a medicine or dietary supplement.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists
Solt, L. A., Wang, Y., Banerjee, S., et al., 2012, Nature - Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy
Woldt, E., Sebti, Y., Solt, L. A., et al., 2013, Nature Medicine - The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator
Preitner, N., Damiola, F., Lopez-Molina, L., et al., 2002, Cell - REV-ERBα, a component of the circadian clock, negatively regulates the inflammatory response
Gibbs, J. E., Blaikley, J., Beesley, S., et al., 2009, Nature Medicine - Rev-erbα and Rev-erbβ coordinately protect the circadian clock and normal metabolic function
Cho, H., Zhao, X., Hatori, M., et al., 2012, Cell